| Year |
Citation |
Score |
| 2019 |
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. The Lancet. Oncology. PMID 31806543 DOI: 10.1016/S1470-2045(19)30687-4 |
0.356 |
|
| 2019 |
Finkelstein DM, Horick NK, Ramchandani R, Boyd KL, Rana HQ, Bychkovsky BL. Are rare cancer survivors at elevated risk of subsequent new cancers? Bmc Cancer. 19: 166. PMID 30791872 DOI: 10.1186/S12885-019-5358-1 |
0.323 |
|
| 2019 |
Finkelstein DM, Schoenfeld DA. Graphing the Win Ratio and its components over time. Statistics in Medicine. 38: 53-61. PMID 30206956 DOI: 10.1002/Sim.7895 |
0.342 |
|
| 2018 |
Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Frontiers in Oncology. 8: 156. PMID 29872641 DOI: 10.3389/Fonc.2018.00156 |
0.387 |
|
| 2018 |
Coleman RE, Finkelstein D, Barrios CH, Martin M, Iwata H, Glaspy JA, Zhou Y, Jandial D, Chan A. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. Journal of Clinical Oncology. 36: 501-501. DOI: 10.1200/Jco.2018.36.15_Suppl.501 |
0.344 |
|
| 2017 |
Reyes S, Horick N, Clark J, Murphy J, Blaszkowsky L, Allen J, Ryan DP, Hong T, Wo J, Nipp R, Parikh A, Faris J, Kwak E, Galway A, Knowles M, ... ... Finkelstein D, et al. Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii145-iii146. PMID 32135779 DOI: 10.1093/Annonc/Mdx262.020 |
0.321 |
|
| 2017 |
Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, MacLeay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, ... ... Finkelstein DM, et al. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor Positive Breast Cancer. Cancer Discovery. PMID 29242214 DOI: 10.1158/2159-8290.Cd-17-0535 |
0.363 |
|
| 2017 |
Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, Rutherford TJ, Brewster WR, O'Malley DM, Partridge EE, Boggess J, ... ... Finkelstein DM, et al. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28143870 DOI: 10.1158/1078-0432.Ccr-15-2750 |
0.311 |
|
| 2017 |
Chavarri-Guerra Y, Louis JS, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011. The Breast. 31: 197-201. PMID 27894048 DOI: 10.1016/J.Breast.2016.11.014 |
0.379 |
|
| 2016 |
Horick NK, Manful A, Lowery J, Domchek S, Moorman P, Griffin C, Visvanathan K, Isaacs C, Kinney AY, Finkelstein DM. Physical and psychological health in rare cancer survivors. Journal of Cancer Survivorship : Research and Practice. PMID 27761785 DOI: 10.1007/S11764-016-0573-0 |
0.317 |
|
| 2016 |
Schoenfeld DA, Finkelstein DM. Assessing survival benefit when treatment delays disease progression. Clinical Trials (London, England). PMID 26908538 DOI: 10.1177/1740774515625990 |
0.327 |
|
| 2016 |
Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, ... Finkelstein DM, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer (Oxford, England : 1990). 56: 85-92. PMID 26829011 DOI: 10.1016/J.Ejca.2015.12.024 |
0.411 |
|
| 2015 |
Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, ... Finkelstein DM, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research : Bcr. 17: 56. PMID 25888246 DOI: 10.1186/S13058-015-0568-1 |
0.387 |
|
| 2015 |
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, et al. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1902-9. PMID 25847936 DOI: 10.1200/Jco.2014.57.6660 |
0.406 |
|
| 2015 |
Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, ... ... Finkelstein DM, et al. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. European Journal of Cancer (Oxford, England : 1990). 51: 685-96. PMID 25752740 DOI: 10.1016/J.Ejca.2015.02.005 |
0.382 |
|
| 2015 |
Strasser-Weippl K, Ramchandani R, Fan L, Li J, Hurlbert M, Finkelstein D, Shao ZM, Goss PE. Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Research and Treatment. 149: 255-61. PMID 25504083 DOI: 10.1007/S10549-014-3219-9 |
0.31 |
|
| 2014 |
Chavarri-Guerra Y, Higgins MJ, Szymonifka J, Cigler T, Liedke P, Partridge A, Ligibel J, Come SE, Finkelstein D, Ryan PD, Goss PE. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. British Journal of Cancer. 111: 2046-50. PMID 25233398 DOI: 10.1038/Bjc.2014.502 |
0.356 |
|
| 2014 |
Chavarri-Guerra Y, St Louis J, Liedke PE, Symecko H, Villarreal-Garza C, Mohar A, Finkelstein DM, Goss PE. Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective. Bmc Cancer. 14: 658. PMID 25199766 DOI: 10.1186/1471-2407-14-658 |
0.336 |
|
| 2014 |
Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. The Lancet. Oncology. 15: e279-89. PMID 24872111 DOI: 10.1016/S1470-2045(13)70567-9 |
0.34 |
|
| 2014 |
Dwojak SM, Finkelstein DM, Emerick KS, Lee JH, Petereit DG, Deschler DG. Poor Survival for American Indians with Head and Neck Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 151: 265-271. PMID 24781656 DOI: 10.1177/0194599814533083 |
0.31 |
|
| 2014 |
Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, ... Finkelstein DM, et al. Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Research and Treatment. 145: 233-43. PMID 24696430 DOI: 10.1007/S10549-014-2928-4 |
0.365 |
|
| 2014 |
Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2296-303. PMID 24687830 DOI: 10.1200/Jco.2013.52.9867 |
0.349 |
|
| 2014 |
Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 601-10. PMID 24501379 DOI: 10.1158/1055-9965.Epi-13-1085 |
0.308 |
|
| 2014 |
Finkelstein DM, Schoenfeld DA. A joint test for progression and survival with interval-censored data from a cancer clinical trial. Statistics in Medicine. 33: 1981-9. PMID 24500790 DOI: 10.1002/Sim.6096 |
0.387 |
|
| 2014 |
Liedke PE, Finkelstein DM, Szymonifka J, Barrios CH, Chavarri-Guerra Y, Bines J, Vasconcelos C, Simon SD, Goss PE. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 126-33. PMID 24165578 DOI: 10.1158/1055-9965.Epi-13-0693 |
0.403 |
|
| 2014 |
Horick N, Manful A, Kinney A, Lowery J, Domchek SM, Isaacs C, Visvanathan K, Griffin CA, Moorman P, Finkelstein DM. Late effects in rare cancer registrants. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E20577 |
0.325 |
|
| 2014 |
Isakoff SJ, He L, Mayer EL, Goss PE, Traina TA, Carey LA, Krag K, Liu MC, Rugo HS, Stearns V, Come SE, Ryan PD, Finkelstein DM, Hartman A, Garber JE, et al. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. Journal of Clinical Oncology. 32: 1020-1020. DOI: 10.1200/Jco.2014.32.15_Suppl.1020 |
0.376 |
|
| 2013 |
Specht MC, Miller CL, Russell TA, Horick N, Skolny MN, O'Toole JA, Jammallo LS, Niemierko A, Sadek BT, Shenouda MN, Finkelstein DM, Smith BL, Taghian AG. Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Research and Treatment. 140: 485-94. PMID 23912961 DOI: 10.1007/S10549-013-2655-2 |
0.375 |
|
| 2013 |
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. Journal of the National Cancer Institute. 105: 1036-42. PMID 23812955 DOI: 10.1093/Jnci/Djt146 |
0.427 |
|
| 2013 |
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ding B, Maniar T, Coleman RE. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps662 |
0.397 |
|
| 2013 |
Guerra YC, Chan A, Finkelstein DM, Chan VF, Harvey VJ, Lee KS, Jain MM, Petrakova K, Raina V, Xu B, Gomez H, Rappold E, Kaneko T, Huang Y, Goss PE. Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial. Journal of Clinical Oncology. 31: 628-628. DOI: 10.1200/Jco.2013.31.15_Suppl.628 |
0.359 |
|
| 2013 |
Sajjadi A, Wanyo C, Specht M, Schapira L, Moy B, Bardia A, Finkelstein D, Boas D, Carp S, Isakoff S. Abstract P4-02-01: Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy using dynamic tomographic optical breast imaging (TOBI) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-02-01 |
0.34 |
|
| 2013 |
Goss P, Barrios C, Chan A, Finkelstein D, Iwata H, Martin M, Braun A, Zhou Y, Maniar T, Coleman R. Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-6-02 |
0.428 |
|
| 2012 |
Nehra D, Oyarvide VM, Mino-Kenudson M, Thayer SP, Ferrone CR, Wargo JA, Muzikansky A, Finkelstein D, Warshaw AL, Castillo CF. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. 12: 358-63. PMID 22898638 DOI: 10.1016/J.Pan.2012.05.011 |
0.33 |
|
| 2012 |
Chávarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM, Goss PE. Breast cancer in Mexico: a growing challenge to health and the health system. The Lancet. Oncology. 13: e335-43. PMID 22846838 DOI: 10.1016/S1470-2045(12)70246-2 |
0.331 |
|
| 2012 |
Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. The Lancet. Oncology. 13: e95-e102. PMID 22381937 DOI: 10.1016/S1470-2045(11)70323-0 |
0.354 |
|
| 2012 |
Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, Braun AH, Ke C, Maniar T, Coleman RE. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial. Journal of Clinical Oncology. 30: TPS670-TPS670. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps670 |
0.409 |
|
| 2012 |
Boyle F, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Buzdar A, Fumoleau P, Gradishar WJ, Martin M, Moy B, Piccart-Gebhart MJ, Pritchard KI, Lindquist D, Amonkar M, Huang Y, ... ... Finkelstein DM, et al. Lapatinib in HER2+ early breast cancer: Quality of life analysis. Journal of Clinical Oncology. 30: 604-604. DOI: 10.1200/Jco.2012.30.15_Suppl.604 |
0.335 |
|
| 2012 |
Smith IE, Finkelstein DM, O'Shaughnessy J, Moy B, Ejlertsen B, Kaufmann M, Buzdar A, Fumoleau P, Gradishar WJ, Martin M, Boyle F, Piccart-Gebhart MJ, Pritchard KI, Lindquist D, Rappold E, et al. Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. Journal of Clinical Oncology. 30: 596-596. DOI: 10.1200/Jco.2012.30.15_Suppl.596 |
0.347 |
|
| 2012 |
Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Finkelstein D, Hartman A, Garber J, Ryan P, Winer E, et al. Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd09-03 |
0.38 |
|
| 2012 |
Carp S, Wanyo C, Specht M, Schapira L, Moy B, Finkelstein D, Boas D, Isakoff S. Abstract P3-06-27: Dynamic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-06-27 |
0.357 |
|
| 2012 |
Goss P, Barrios C, Chan A, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Coleman R. Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Ot2-3-03 |
0.423 |
|
| 2012 |
Coleman RE, Barrios C, Bell R, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T, Goss PE. Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32883-0 |
0.418 |
|
| 2011 |
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun AH, Dansey RD, Coleman RE. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS152. PMID 28022982 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps152 |
0.363 |
|
| 2011 |
Goss PE, Barrios CH, Chan A, Chia SK, Delaloge S, Ejlertsen B, Ingle JN, Moy B, Iwata H, Holmes FA, Mansi J, Von Minckwitz G, Han L, Thiele A, Agrapart V, ... ... Finkelstein D, et al. A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS137. PMID 28022891 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps137 |
0.348 |
|
| 2011 |
Cigler T, Higgins MJ, Szymonifka J, Partridge AH, Ligibel JA, Finkelstein D, Come SE, Ryan PD, Goss PE. A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 559. PMID 28021407 DOI: 10.1200/Jco.2011.29.15_Suppl.559 |
0.371 |
|
| 2011 |
Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, et al. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1025. PMID 28020734 DOI: 10.1200/Jco.2011.29.15_Suppl.1025 |
0.339 |
|
| 2011 |
Sgroi D, Carney E, Richardson E, Steffel L, Binns SN, Finkelstein DM, Shepherd LE, Kesty NC, Schnabel C, Erlander MG, Ingle JN, Porter P, Paik S, Muss HB, Pritchard KI, et al. Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2. PMID 27958176 DOI: 10.1200/Jco.2011.29.27_Suppl.2 |
0.368 |
|
| 2011 |
Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, ... ... Finkelstein DM, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prevention Research (Philadelphia, Pa.). 4: 1401-8. PMID 21893500 DOI: 10.1158/1940-6207.Capr-10-0402 |
0.301 |
|
| 2011 |
Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C, Griffin CA, Moorman PG, Edwards KL, Hill DA, Berg JS, Tomlinson GE, Anton-Culver H, Strong LC, Kasten CH, ... Finkelstein DM, et al. Clinically relevant changes in family history of cancer over time. Jama. 306: 172-8. PMID 21750294 DOI: 10.1001/Jama.2011.955 |
0.316 |
|
| 2011 |
Schoenfeld DA, Rajicic N, Ficociello LH, Finkelstein DM. A test for the relationship between a time-varying marker and both recovery and progression with missing data. Statistics in Medicine. 30: 718-24. PMID 21394748 DOI: 10.1002/Sim.4145 |
0.332 |
|
| 2011 |
Finkelstein DM, Schoenfeld DA. Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1093-5. PMID 21321297 DOI: 10.1200/Jco.2010.33.9374 |
0.321 |
|
| 2011 |
Carp SA, Wanyo C, Specht M, Schapira L, Moy B, Finkelstein D, Boas D, Isakoff SJ. Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. Journal of Clinical Oncology. 29: 10607-10607. DOI: 10.1200/Jco.2011.29.15_Suppl.10607 |
0.324 |
|
| 2011 |
Lowery JT, Marcus A, Horick N, Finkelstein D, Ahnen DJ. Awareness and uptake of genetic testing among individuals at-risk for hereditary colon cancer Hereditary Cancer in Clinical Practice. 9. DOI: 10.1186/1897-4287-9-S1-P22 |
0.301 |
|
| 2011 |
Goss P, Smith I, O'Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard K, Aktan G, Rappold E, ... ... Finkelstein D, et al. S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S4-7 |
0.338 |
|
| 2011 |
Chavarri-Guerra Y, Liedke P, Symecko H, Moy B, Higgins M, Louis JS, Finkelstein D, Goss P. P1-12-26: Global Patterns of Care for HER2/Neu Overexpressing Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-12-26 |
0.387 |
|
| 2011 |
Chavarri-Guerra Y, Liedke P, Symecko H, Hammond E, Higgins M, Finkelstein D, Goss P. P1-11-12: Patterns of Care of Newly Diagnosed Patients with Breast Cancer in Mexico. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-11-12 |
0.369 |
|
| 2011 |
Liedke P, Szymonifka J, Simon S, Barrios C, Bines J, Finkelstein D, Goss P. P1-08-17: Pregnancy-Associated Breast Cancer Does Not Have a Worse Outcome in the 4912 Women with Breast Cancer of the AMAZONA Project. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-08-17 |
0.335 |
|
| 2011 |
Goss P, Barrios C, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Braun S, Dansey R, Coleman R. OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot1-01-03 |
0.405 |
|
| 2011 |
Rizvi I, Celli JP, Xu F, Evans CL, Abu-Yousif AO, Muzikansky A, Elrington SA, Pogue BW, Finkelstein DM, Demirci U, Hasan T. Biologically relevant 3D tumor arrays: Treatment response and the importance of stromal partners Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7886. DOI: 10.1117/12.875892 |
0.34 |
|
| 2010 |
Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, Finkelstein D, Hasan T. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Research. 70: 9319-28. PMID 21062986 DOI: 10.1158/0008-5472.Can-10-1783 |
0.344 |
|
| 2010 |
Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, ... ... Finkelstein DM, et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Research and Treatment. 124: 441-51. PMID 20309627 DOI: 10.1007/S10549-010-0842-Y |
0.308 |
|
| 2010 |
Crippa S, Fernández-Del Castillo C, Salvia R, Finkelstein D, Bassi C, Domínguez I, Muzikansky A, Thayer SP, Falconi M, Mino-Kenudson M, Capelli P, Lauwers GY, Partelli S, Pederzoli P, Warshaw AL. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 8: 213-9. PMID 19835989 DOI: 10.1016/J.Cgh.2009.10.001 |
0.359 |
|
| 2010 |
Finkelstein DM, Wang R, Ficociello LH, Schoenfeld DA. A score test for association of a longitudinal marker and an event with missing data. Biometrics. 66: 726-32. PMID 19754923 DOI: 10.1111/J.1541-0420.2009.01326.X |
0.315 |
|
| 2010 |
Sgroi D, Finkelstein D, Shepherd L, Ingle J, Rimm D, Sasano H, Porter P, Pins M, Paik S, Ristimaki A, Pritchard K, Tu D, Goss P. Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-26 |
0.416 |
|
| 2009 |
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. 101: 465-72. PMID 19603024 DOI: 10.1038/Sj.Bjc.6605164 |
0.343 |
|
| 2009 |
Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, Aisenberg AC, Taghian AG. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. International Journal of Radiation Oncology, Biology, Physics. 73: 69-74. PMID 18538497 DOI: 10.1016/J.Ijrobp.2008.03.066 |
0.351 |
|
| 2007 |
Ficociello LH, Perkins BA, Silva KH, Finkelstein DM, Ignatowska-Switalska H, Gaciong Z, Cupples LA, Aschengrau A, Warram JH, Krolewski AS. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clinical Journal of the American Society of Nephrology : Cjasn. 2: 461-9. PMID 17699452 DOI: 10.2215/Cjn.03691106 |
0.309 |
|
| 2007 |
Matthews AG, Finkelstein DM, Betensky RA. Multivariate logistic regression for familial aggregation in age at disease onset. Lifetime Data Analysis. 13: 191-209. PMID 17410428 DOI: 10.1007/S10985-007-9037-1 |
0.309 |
|
| 2007 |
Hughes KS, El-Din MAA, Betts K, Finkelstein DM, Aisenberg AC, Taghian AG. Breast Cancer After Supradiaphragmatic Irradiation for Hodgkin's Disease; Risk Analysis and Possible Surveillance Strategies International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.049 |
0.333 |
|
| 2005 |
Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 104: 1418-27. PMID 16116597 DOI: 10.1002/Cncr.21312 |
0.364 |
|
| 2003 |
Anton-Culver H, Ziogas A, Bowen D, Finkelstein D, Griffin C, Hanson J, Isaacs C, Kasten-Sportes C, Mineau G, Nadkarni P, Rimer B, Schildkraut J, Strong L, Weber B, Winn D, et al. The Cancer Genetics Network: recruitment results and pilot studies. Community Genetics. 6: 171-7. PMID 15237201 DOI: 10.1159/000078165 |
0.332 |
|
| 2003 |
Ancukiewicz M, Finkelstein DM, Schoenfeld DA. Modelling the relationship between continuous covariates and clinical events using isotonic regression Statistics in Medicine. 22: 3151-3159. PMID 14518020 DOI: 10.1002/Sim.1561 |
0.303 |
|
| 2003 |
Pierie JPEN, Choudry UH, Muzikansky A, Finkelstein DM, Ott MJ. Prognosis and management of extramammary Paget's disease and the association with secondary malignancies. Journal of the American College of Surgeons. 196: 45-50. PMID 12517548 DOI: 10.1016/S1072-7515(02)01619-8 |
0.368 |
|
| 2002 |
Pauler DK, Finkelstein DM. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Statistics in Medicine. 21: 3897-3911. PMID 12483774 DOI: 10.1002/Sim.1392 |
0.362 |
|
| 2002 |
Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer (Amsterdam, Netherlands). 37: 311-8. PMID 12234701 DOI: 10.1016/S0169-5002(02)00074-0 |
0.371 |
|
| 2002 |
Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer. 94: 305-13. PMID 11900216 DOI: 10.1002/Cncr.10223 |
0.349 |
|
| 2002 |
DiRienzo AG, van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. Aids Research and Human Retroviruses. 18: 89-94. PMID 11839141 DOI: 10.1089/08892220252779629 |
0.314 |
|
| 2001 |
Goggins WB, Finkelstein DM, Zaslavsky AM. Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censored. Biometrics. 55: 445-51. PMID 11318198 DOI: 10.1111/J.0006-341X.1999.00445.X |
0.308 |
|
| 2001 |
Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer. 91: 874-880. PMID 11241258 DOI: 10.1002/1097-0142(20010215)91:4<874::Aid-Cncr1076>3.0.Co;2-O |
0.31 |
|
| 2001 |
Breathnach OS, Kwiatkowski DJ, Finkelstein DM, Godleski J, Sugarbaker DJ, Johnson BE, Mentzer S. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. The Journal of Thoracic and Cardiovascular Surgery. 121: 42-7. PMID 11135158 DOI: 10.1067/Mtc.2001.110190 |
0.328 |
|
| 2001 |
Finkelstein DM, Schoenfeld DA. Comparing treatment strategies using a synthesized clinical trial: An analysis of late versus early use of trimethoprim-sulfamethoxazole for AIDS patients Journal of Statistical Planning and Inference. 96: 179-189. DOI: 10.1016/S0378-3758(00)00334-7 |
0.347 |
|
| 2000 |
Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles Proceedings of the National Academy of Sciences of the United States of America. 97: 11451-11454. PMID 11027344 DOI: 10.1073/Pnas.97.21.11451 |
0.324 |
|
| 2000 |
Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS clinical trials group 268 Journal of Acquired Immune Deficiency Syndromes. 24: 337-343. PMID 11015150 DOI: 10.1097/00126334-200008010-00007 |
0.308 |
|
| 2000 |
Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma Archives of Dermatology. 136: 1118-1122. PMID 10987867 DOI: 10.1001/Archderm.136.9.1118 |
0.331 |
|
| 2000 |
Goggins WB, Finkelstein DM. A Proportional Hazards Model for Multivariate Interval-Censored Failure Time Data Biometrics. 56: 940-943. PMID 10985240 DOI: 10.1111/J.0006-341X.2000.00940.X |
0.31 |
|
| 2000 |
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 56: 779-788. PMID 10985216 DOI: 10.1111/J.0006-341X.2000.00779.X |
0.353 |
|
| 2000 |
Domchek SM, Younger J, Finkelstein DM, MVSMD. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 89: 363-368. PMID 10918167 DOI: 10.1002/1097-0142(20000715)89:2<363::Aid-Cncr22>3.0.Co;2-3 |
0.335 |
|
| 2000 |
Chakravatri A, Zehr EM, Zietman AL, Shipley WU, Goggins WB, Finkelstein DM, Young RH, Chang EL, Wu C. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. Urology. 55: 635-638. PMID 10792068 DOI: 10.1016/S0090-4295(00)00462-3 |
0.332 |
|
| 2000 |
Myojin M, Choi NC, Wright CD, Wain JC, Harris N, Hug EB, Mathisen DJ, Lynch T, Carey RW, Grossbard M, Finkelstein DM, Grillo HC. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study International Journal of Radiation Oncology Biology Physics. 46: 927-933. PMID 10705015 DOI: 10.1016/S0360-3016(99)00514-3 |
0.335 |
|
| 2000 |
Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer. 88: 180-5. PMID 10618622 DOI: 10.1002/(Sici)1097-0142(20000101)88:1<180::Aid-Cncr25>3.0.Co;2-Q |
0.314 |
|
| 1999 |
Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 24: 897-902. PMID 10516703 DOI: 10.1038/Sj.Bmt.1702004 |
0.334 |
|
| 1999 |
Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials Statistics in Medicine. 18: 1341-1354. PMID 10399200 DOI: 10.1002/(Sici)1097-0258(19990615)18:11<1341::Aid-Sim129>3.0.Co;2-7 |
0.304 |
|
| 1999 |
Ott MJ, Tanabe KK, Gadd MA, Stark P, Smith BL, Finkelstein DM, Souba WW. Multimodality management of Merkel cell carcinoma. Archives of Surgery (Chicago, Ill. : 1960). 134: 388-92; discussion 3. PMID 10199311 DOI: 10.1001/Archsurg.134.4.388 |
0.369 |
|
| 1998 |
Wenkel E, Thornton AF, Finkelstein D, Adams J, Lyons S, Monte SDL, Ojeman RG, Munzenrider JE. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. International Journal of Radiation Oncology Biology Physics. 48: 1363-1370. PMID 11121635 DOI: 10.1016/S0360-3016(00)01411-5 |
0.353 |
|
| 1998 |
Santoni R, NLMD, Finkelstein DM, Hug E, Hanssens P, Goitein M, Smith AR, O’Farrell D, Efird JT, Fullerton B, Munzenrider JE. Temporal Lobe (TL) Damage Following Surgery and High-Dose Photon and Proton Irradiation in 96 Patients Affected by Chordomas and Chondrosarcomas of the Base of the Skull International Journal of Radiation Oncology Biology Physics. 41: 59-68. PMID 9588918 DOI: 10.1016/S0360-3016(98)00031-5 |
0.325 |
|
| 1997 |
Finkelstein DM, Schoenfeld DA, Stamenovic E. Analysis of multiple failure time data from an AIDS clinical trial Statistics in Medicine. 16: 951-961. PMID 9160491 DOI: 10.1002/(Sici)1097-0258(19970430)16:8<951::Aid-Sim547>3.0.Co;2-5 |
0.31 |
|
| 1997 |
Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. The New England Journal of Medicine. 336: 1416-21. PMID 9145678 DOI: 10.1056/Nejm199705153362003 |
0.317 |
|
| 1997 |
Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 79: 1203-10. PMID 9070499 DOI: 10.1002/(Sici)1097-0142(19970315)79:6<1203::Aid-Cncr20>3.0.Co;2-2 |
0.35 |
|
| 1997 |
Amrein PC, Colecchi CH, Finkelstein DM, Fabian RL. Adjuvant Chemotherapy in Advanced Head and Neck Cancer. Oncologist. 2: 135-141. DOI: 10.1634/Theoncologist.2-3-135 |
0.385 |
|
| 1996 |
Debus J, Hug EB, Liebsch NJ, O'Farrel D, Finkelstein D, Efird J, Munzenrider JE. Brainstem tolerance to conformal radiotherapy of skull base tumors. International Journal of Radiation Oncology Biology Physics. 39: 967-975. PMID 9392533 DOI: 10.1016/S0360-3016(97)00364-7 |
0.32 |
|
| 1996 |
Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. Journal of Neurosurgery. 85: 602-7. PMID 8814163 DOI: 10.3171/Jns.1996.85.4.0602 |
0.357 |
|
| 1996 |
Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, Cheung T, Soeiro R, Hojczyk P, Black JR. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Annals of Internal Medicine. 124: 792-802. PMID 8610948 DOI: 10.7326/0003-4819-124-9-199605010-00003 |
0.369 |
|
| 1996 |
Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 11: 379-384. PMID 8601224 DOI: 10.1097/00042560-199604010-00008 |
0.339 |
|
| 1996 |
FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. The New England Journal of Medicine. 334: 143-9. PMID 8531968 DOI: 10.1056/Nejm199601183340302 |
0.319 |
|
| 1995 |
Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, Phillips L, Craven D, van der Horst C, Feinberg J. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. The New England Journal of Medicine. 332: 693-9. PMID 7854375 DOI: 10.1056/Nejm199503163321101 |
0.35 |
|
| 1995 |
Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An eastern cooperative oncology group study Journal of Clinical Oncology. 13: 1430-1435. PMID 7751889 DOI: 10.1200/Jco.1995.13.6.1430 |
0.382 |
|
| 1994 |
Bonomi P, Finkelstein D, Chang AY. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology. 17: 215-217. PMID 8192104 DOI: 10.1097/00000421-199406000-00006 |
0.348 |
|
| 1994 |
Black JR, Feinberg J, Murphy RL, Fass RJ, Finkelstein D, Akil B, Safrin S, Carey JT, Stansell J, Plouffe JF, He W. Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044 Clinical Infectious Diseases. 18: 905-913. PMID 8086551 DOI: 10.1093/Clinids/18.6.905 |
0.334 |
|
| 1994 |
Finkelstein DM, Schoenfeld DA. Analysing survival in the presence of an auxiliary variable Statistics in Medicine. 13: 1747-1754. PMID 7997708 DOI: 10.1002/Sim.4780131706 |
0.323 |
|
| 1993 |
Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan TT, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 11: 561-569. PMID 8445432 DOI: 10.1200/Jco.1993.11.3.561 |
0.404 |
|
| 1993 |
Schoenfeld DA, Finkelstein DM, Richman DD. Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-point Aids. 7: 955-958. PMID 8102853 DOI: 10.1097/00002030-199307000-00008 |
0.323 |
|
| 1992 |
Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, Powderly WG, Steigbigel RT, Zuger A, Holzman RS. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS clinical trials group protocol 021 New England Journal of Medicine. 327: 1842-1848. PMID 1448121 DOI: 10.1056/Nejm199212243272604 |
0.357 |
|
| 1992 |
Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi PD. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. Journal of the National Cancer Institute. 84: 1077-1084. PMID 1320131 DOI: 10.1093/Jnci/84.14.1077 |
0.387 |
|
| 1992 |
Ellenberg SS, Finkelstein DM, Schoenfeld DA. Statistical issues arising in aids clinical trials Journal of the American Statistical Association. 87: 562-569. DOI: 10.1080/01621459.1992.10475240 |
0.313 |
|
| 1990 |
Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, Ruckdeschel JC. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer Investigational New Drugs. 8: 183-185. PMID 2166720 DOI: 10.1007/Bf00177255 |
0.325 |
|
| 1990 |
Green SB, Ellenberg SS, Finkelstein D, Forsythe AB, Freedman LS, Freeman K, Lefkopoulou M, Schoenfeld D, Smith RP. Issues in the design of drug trials for AIDS Controlled Clinical Trials. 11: 80-87. PMID 2161314 DOI: 10.1016/0197-2456(90)90002-J |
0.31 |
|
| 1990 |
Aisner SC, Finkelstein DM, Ettinger DS, Abeloff MD, Ruckdeschel JC, Eggleston JC. The clinical significance of variant-morphology small-cell carcinoma of the lung. Journal of Clinical Oncology. 8: 402-408. PMID 2155311 DOI: 10.1200/Jco.1990.8.3.402 |
0.32 |
|
| 1990 |
Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 8: 230-240. PMID 2153765 DOI: 10.1200/Jco.1990.8.2.230 |
0.375 |
|
| 1989 |
Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1602-13. PMID 2553879 DOI: 10.1200/Jco.1989.7.11.1602 |
0.392 |
|
| 1989 |
Ettinger DS, Finkelstein DM, Donehower RC, Chang AYC, Green M, Blum R, Hahn RG, Ruckdeschel JC. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study. Medical and Pediatric Oncology. 17: 197-201. PMID 2546026 DOI: 10.1002/Mpo.2950170306 |
0.326 |
|
| 1988 |
Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the Functional Living Index-Cancer (FLIC) scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study American Journal of Clinical Oncology: Cancer Clinical Trials. 11: 630-633. PMID 3055933 DOI: 10.1097/00000421-198812000-00007 |
0.33 |
|
| 1986 |
Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study Journal of Clinical Oncology. 4: 702-709. PMID 3701389 DOI: 10.1200/Jco.1986.4.5.702 |
0.366 |
|
| 1986 |
Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer Journal of Clinical Oncology. 4: 14-22. PMID 3510278 DOI: 10.1200/Jco.1986.4.1.14 |
0.37 |
|
| 1986 |
Finkelstein DM. A proportional hazards model for interval-censored failure time data. Biometrics. 42: 845-854. DOI: 10.2307/2530698 |
0.305 |
|
| 1985 |
Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V - a randomized comparison of four cisplatin-containing regimens Journal of Clinical Oncology. 3: 72-79. PMID 3880810 DOI: 10.1200/Jco.1985.3.1.72 |
0.344 |
|
| 1985 |
Finkelstein DM, Wolfe RA. A semiparametric model for regression analysis of interval-censored failure time data. Biometrics. 41: 933-945. DOI: 10.2307/2530965 |
0.354 |
|
| Show low-probability matches. |